These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Impact of chronic migraine attacks and their severity on the endogenous μ-opioid neurotransmission in the limbic system. Jassar H; Nascimento TD; Kaciroti N; DosSantos MF; Danciu T; Koeppe RA; Smith YR; Bigal ME; Porreca F; Casey KL; Zubieta JK; DaSilva AF Neuroimage Clin; 2019; 23():101905. PubMed ID: 31279240 [TBL] [Abstract][Full Text] [Related]
27. Low μ-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis. Hermann D; Hirth N; Reimold M; Batra A; Smolka MN; Hoffmann S; Kiefer F; Noori HR; Sommer WH; Reischl G; la Fougère C; Mann K; Spanagel R; Hansson AC Neuropsychopharmacology; 2017 Feb; 42(3):606-614. PubMed ID: 27510425 [TBL] [Abstract][Full Text] [Related]
28. It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder. Hsu DT; Sanford BJ; Meyers KK; Love TM; Hazlett KE; Walker SJ; Mickey BJ; Koeppe RA; Langenecker SA; Zubieta JK Mol Psychiatry; 2015 Feb; 20(2):193-200. PubMed ID: 25600108 [TBL] [Abstract][Full Text] [Related]
29. Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects. Johansson J; Hirvonen J; Lovró Z; Ekblad L; Kaasinen V; Rajasilta O; Helin S; Tuisku J; Sirén S; Pennanen M; Agrawal A; Crystal R; Vainio PJ; Alho H; Scheinin M Neuropsychopharmacology; 2019 Aug; 44(9):1667-1673. PubMed ID: 30867551 [TBL] [Abstract][Full Text] [Related]
30. Investigation of [ Kelleher AC; Pearson TD; Ramsey J; Zhao W; O'Conor KA; Bakhoda A; Stodden T; Guo M; Eisenberg SM; Shah SV; Freaney ML; Kim W; Kang Y; Tomasi D; Johnson C; Fang CA; Volkow ND; Kim SW Sci Rep; 2024 Jul; 14(1):16250. PubMed ID: 39009645 [TBL] [Abstract][Full Text] [Related]
34. μ-Opioid receptor availability in the amygdala is associated with smoking for negative affect relief. Falcone M; Gold AB; Wileyto EP; Ray R; Ruparel K; Newberg A; Dubroff J; Logan J; Zubieta JK; Blendy JA; Lerman C Psychopharmacology (Berl); 2012 Aug; 222(4):701-8. PubMed ID: 22389047 [TBL] [Abstract][Full Text] [Related]
35. Opioid Release after High-Intensity Interval Training in Healthy Human Subjects. Saanijoki T; Tuominen L; Tuulari JJ; Nummenmaa L; Arponen E; Kalliokoski K; Hirvonen J Neuropsychopharmacology; 2018 Jan; 43(2):246-254. PubMed ID: 28722022 [TBL] [Abstract][Full Text] [Related]
36. Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Zubieta JK; Ketter TA; Bueller JA; Xu Y; Kilbourn MR; Young EA; Koeppe RA Arch Gen Psychiatry; 2003 Nov; 60(11):1145-53. PubMed ID: 14609890 [TBL] [Abstract][Full Text] [Related]
37. Mapping neurotransmitter networks with PET: an example on serotonin and opioid systems. Tuominen L; Nummenmaa L; Keltikangas-Järvinen L; Raitakari O; Hietala J Hum Brain Mapp; 2014 May; 35(5):1875-84. PubMed ID: 23671038 [TBL] [Abstract][Full Text] [Related]
38. Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Bencherif B; Wand GS; McCaul ME; Kim YK; Ilgin N; Dannals RF; Frost JJ Biol Psychiatry; 2004 Feb; 55(3):255-62. PubMed ID: 14744466 [TBL] [Abstract][Full Text] [Related]
39. Building up analgesia in humans via the endogenous μ-opioid system by combining placebo and active tDCS: a preliminary report. DosSantos MF; Martikainen IK; Nascimento TD; Love TM; DeBoer MD; Schambra HM; Bikson M; Zubieta JK; DaSilva AF PLoS One; 2014; 9(7):e102350. PubMed ID: 25029273 [TBL] [Abstract][Full Text] [Related]
40. Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Scott DJ; Domino EF; Heitzeg MM; Koeppe RA; Ni L; Guthrie S; Zubieta JK Neuropsychopharmacology; 2007 Feb; 32(2):450-7. PubMed ID: 17091130 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]